ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Neoplasm Metastasis
Adenocarcinoma
Lung Cancer
Non-Small-Cell Lung Carcinoma

Colon Cancer trials near San Francisco, CA, USA:

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142)

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in mea ...

Active, not recruiting
Microsatellite Unstable Colorectal Cancer
Microsatellite Stable Colorectal Cancer
Drug: Ipilimumab
Drug: Daratumumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Francisco, California, United States and 32 other locations

to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...

Enrolling
Colon Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

San Francisco, California, United States and 83 other locations

the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

Phase 2, Phase 3

NRG Oncology

San Francisco, California, United States and 831 other locations

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Drug: Assigned interventions

Phase 1

Revolution Medicines
Revolution Medicines

Stanford, California, United States and 12 other locations

known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Squamous Cell Cancer of Head and Neck (SCCHN)
Drug: TAK-186

Phase 1, Phase 2

Takeda
Takeda

San Francisco, California, United States and 17 other locations

clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer...

Active, not recruiting
Metastatic Breast Cancer
HER2-negative Breast Cancer
Drug: Fruquintinib (HMPL-013)

Phase 1

HUTCHMED
HUTCHMED

Santa Rosa, California, United States and 8 other locations

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemipl...

Enrolling
Breast Cancer
Colon Cancer
Biological: Cemiplimab
Biological: E-602

Phase 1, Phase 2

Palleon Pharmaceuticals

Stanford, California, United States and 12 other locations

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor...

Enrolling
Colorectal Cancer (CRC)
Non-Small Cell Lung Cancer (NSCLC)
Drug: RMC-6291

Phase 1

Revolution Medicines
Revolution Medicines

San Francisco, California, United States and 63 other locations

This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in parti...

Enrolling
Metastatic Cancer
Solid Tumors, Adult
Procedure: Positron Emission Tomography (PET) imaging
Drug: Gallium-68 labelled (68Ga-) FAP-2286

Phase 1

Thomas Hope

San Francisco, California, United States

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: MRTX849
Drug: Afatinib

Phase 1, Phase 2

Mirati Therapeutics
Mirati Therapeutics

Vallejo, California, United States and 97 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems